Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 5/20 | 0.66 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | ESR1 | P03372 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | RECQL | P46063 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.66 |
| ▸ | THPO | P40225 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462572 | 1.00 | ALOX15 (0.66) | ALOX15ALOX12TP53MAPK1HIF1A | |
| SCHEMBL2738991 | 1.00 | ALOX15 (0.66) | ALOX15ALOX12TP53MAPK1HIF1A | |
| SCHEMBL2956883 | 0.85 | ALOX15 (0.66) | ALOX15ALOX12TP53MAPK1HIF1A | |
| SCHEMBL13748214 | 0.83 | ALOX15 (0.63) | ALOX15ALOX12TP53MAPK1HIF1A | |
| SCHEMBL4071418 | 0.81 | ALOX15 (0.61) | ALOX15ALOX12TP53MAPK1HIF1A | |
| SCHEMBL5277808 | 0.81 | ALOX15 (0.71) | ALOX15ALOX12KDM4EMEN1CYP3A4 | |
| SCHEMBL3900627 | 0.81 | FOS (0.71) | ALOX15ALOX12MAPK1ALDH1A1CYP3A4 | |
| SCHEMBL3900634 | 0.81 | FOS (0.71) | ALOX15ALOX12MAPK1ALDH1A1CYP3A4 | |
| SCHEMBL3992083 | 0.81 | NR1I2 (0.46) | ALOX15HSD17B10ALDH1A1CYP2D6SLC6A2 | |
| SCHEMBL5277797 | 0.81 | ALOX15 (0.71) | ALOX15ALOX12KDM4EMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11896670-B2 | Synthesis routes to access MDMA prodrugs by using controlled and non-controlled intermediates | Mind Medicine, Inc. (US) | 2024-02-13 | — | — | US | claimed |
| US-12630504-B2 | Phenethylamine derivatives, compositions, and methods of use | CYBIN IRL LIMITED (IE) | 2026-05-19 | — | — | US | disclosed |
| EP-4724062-A2 | COMPOSITIONS AND METHODS FOR INCREASING EXPOSURE OF R(-)-MDA | EmpathBio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4687880-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | Tactogen Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | TACTOGEN INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4673127-A1 | DEUTERATED AND FLUORINATED EMPATHOGENS | Alexander Shulgin Research Institute, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4611738-A1 | COMPOSITIONS COMPRISING MDMA AND METHODS OF USING SAME | Lykos Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250179042-A1 | USE OF DEUTERATED EMPATHOGENS AS THERAPEUTIC AGENTS | ALEXANDER SHULGIN RES INSTITUTE INC (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250170095-A1 | COMPOSITIONS COMPRISING NON-RACEMIC MIXTURES OF (R)- AND (S)-3,4-METHYLENEDIOXYMETHAMPHETAMINE OR (R) AND (S) N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE AND USES THEREOF | PHARMALA BIOTECH INC. (CA) | 2025-05-29 | — | — | US | disclosed |
| US-20250145566-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2025-05-08 | — | — | US | disclosed |
| US-20230066171-A1 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | Mind Medicine, Inc. (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2023028091-A1 | DEUTERATED EMPATHOGENS | ALEXANDER SHULGIN RESEARCH INSTITUTE (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023028092-A2 | FLUORINATED EMPATHOGENS | ALEXANDER SHULGIN RESEARCH INSTITUTE (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023028022-A1 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | Mind Medicine, Inc. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023019369-A1 | COMPOSITIONS COMPRISING NON-RACEMIC MIXTURES OF (R)- AND (S)-3,4-METHYLENEDIOXYMETHAMPHETAMINE OR (R) AND (S) N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE AND USES THEREOF | PHARMALA BIOTECH INC. (CA) | 2023-02-23 | — | — | WO | disclosed |
| WO-2022106947-A1 | MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY | LIECHTI MATTHIAS EMANUEL (CH) | 2022-05-27 | — | — | WO | disclosed |
| US-20220151986-A1 | MDMA PRODRUGS TO ASSIST PSYCHOTHERAPY | Mind Medicine, Inc. (US) | 2022-05-19 | — | — | US | disclosed |
| WO-2022038171-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | CYBIN IRL LIMITED (IE) | 2022-02-24 | — | — | WO | disclosed |
| WO-2014033555-A2 | SAMPLE COLLECTION DEVICES COMPRISING CONTROLS | CONCATENO UK Ltd. (GB) | 2014-03-06 | — | — | WO | disclosed |
| WO-1994000432-A1 | ANORECTIC EPINEPHRINE DERIVATIVES | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021069-A1 | ADVANTAGEOUS FLUOROBENZOFURANS FOR THE TREATMENT OF MENTAL DISORDERS OR ENHANCEMENT | HCN1, HCN4, CRH | ALOX15 2734/4885ALOX12 2143/4885TP53 4824/4885 |
| US-20250179042-A1 | USE OF DEUTERATED EMPATHOGENS AS THERAPEUTIC AGENTS | SLC18A2, SLC6A3, GAP43 | ALOX15 3783/4885ALOX12 3633/4885TP53 4092/4885 |
| US-12630504-B2 | Phenethylamine derivatives, compositions, and methods of use | HTR2C, HTR1A, HTR2A | ALOX15 3026/4885ALOX12 2015/4885TP53 4547/4885 |
| US-20250170095-A1 | COMPOSITIONS COMPRISING NON-RACEMIC MIXTURES OF (R)- AND (S)-3,4-METHYLENEDIOXYMETHAMPHETAMINE OR (R) AND (S) N-METHYL-1,3-BENZODIOXOLYLBUTANAMINE AND USES THEREOF | DRD3, DRD1, DRD2 | ALOX15 3635/4885ALOX12 3983/4885TP53 4756/4885 |
| US-20250145566-A1 | PHENETHYLAMINE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | PNMT, HTR7, HTR2C | ALOX15 912/4885ALOX12 992/4885TP53 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.